Liquid biopsy testing is a rapidly developing clinical application that is largely driven by new and innovative technologies. Join us on February 21st for this Liquid Biopsy seminar, where Oliver Wachter, Prof. Dr. med. Stefan Holdenrieder, Dr. Pierre-Jean Lamy and Dr. Alexander Sartori will will discuss how liquid biopsy testing is breaking new ground in cancer management. Register early as space is limited.
14:00 Arrival of participants
14:30 “Current possibilities in routine diagnostics and where are we going.” Oliver Wachter, Zentrum für Humangenetik und Laboratoriumsdiagnostik (MVZ) Dr. Klein, Dr. Rost und Kollegen
15:15 “Preanalytical, analytical and clinical considerations for cfDNA diagnostics.” Prof. Dr. med. Stefan Holdenrieder, Director Institut für Laboratoriumsmedizin, Deutsches Herzzentrum München
15:45 Coffee Break
16:00 “Impact on treatment decision depending on method for Liquid Biopsy testing. Comparative study.” Dr. Pierre-Jean Lamy, LaboSud, Montpellier
16:45 “Ultra-sensitive detection of somatic mutations in Liquid Biopsy with the MassARRAY® System.” Dr. Alexander Sartori, Manager Scientific Affairs, Agena Bioscience, Hamburg
17:30 Discussion and Buffet